How Immunotherapy May Work Within Glioblastoma Research
By Rob Sutter
When you're talking about the more prevalent type of tumor in the brain, glioblastoma research is definitely something worth talking about. The potential that this method can possess is one of the greatest that I have seen. There is a high level of work done on the matter, which is tough to argue against. With so many stories posted about the matter, I would like to think that I have placed all of my attention on those which are the most deserving, of which there are many.
For example, an article on Seeking Alpha talked about how the Northwest Biotherapeutics announced a 60-patient Phase I/II trial in order to work towards a related goal. The trial would be done at the MD Anderson Cancer Center and a type of immunotherapy would be put into effect as well. It has been given the name of DCVax-Direct and it will have a standard dose escalation phase, which will play into the Phase II portion. This would then determine a RECIST-measured tumor shrinkage endpoint, displaying a high level of intricacy.
One of the defining features of this experiment is that it makes use of a patient's own bodily cells. This doesn't seem to be much different from stem cell research, which is being conducted right now as well. There are many supporters of this, since they believe that something great will come of it in due time. It's difficult to argue such a thing and I believe that it's easy to make the comparison between one and the other, considering how certain cells are implemented.
Glioblastoma research is an important idea to consider, especially when you think about the common nature of these particular tumors. It seems like these are the ones most seen in an entire group; at least 120 types are known. I don't think that companies the likes of Voices against Brain Cancer will be able to deny this kind of idea, either. Hopefully there is more done in order to help those impacted and that these kinds of stories are reported on in the future.
It's clear that Northwest has done a great deal of good when it comes to this particular method. It seems like even more will be done in the future, as the article talked a phase III trial that would help the patients along. From what I've seen, solid results will come down the pipeline in 2014, which would be great for those working in this field of research. I believe that, with so many details in existence, it seems like even more of them will be able to help those afflicted in the long run.
For example, an article on Seeking Alpha talked about how the Northwest Biotherapeutics announced a 60-patient Phase I/II trial in order to work towards a related goal. The trial would be done at the MD Anderson Cancer Center and a type of immunotherapy would be put into effect as well. It has been given the name of DCVax-Direct and it will have a standard dose escalation phase, which will play into the Phase II portion. This would then determine a RECIST-measured tumor shrinkage endpoint, displaying a high level of intricacy.
One of the defining features of this experiment is that it makes use of a patient's own bodily cells. This doesn't seem to be much different from stem cell research, which is being conducted right now as well. There are many supporters of this, since they believe that something great will come of it in due time. It's difficult to argue such a thing and I believe that it's easy to make the comparison between one and the other, considering how certain cells are implemented.
Glioblastoma research is an important idea to consider, especially when you think about the common nature of these particular tumors. It seems like these are the ones most seen in an entire group; at least 120 types are known. I don't think that companies the likes of Voices against Brain Cancer will be able to deny this kind of idea, either. Hopefully there is more done in order to help those impacted and that these kinds of stories are reported on in the future.
It's clear that Northwest has done a great deal of good when it comes to this particular method. It seems like even more will be done in the future, as the article talked a phase III trial that would help the patients along. From what I've seen, solid results will come down the pipeline in 2014, which would be great for those working in this field of research. I believe that, with so many details in existence, it seems like even more of them will be able to help those afflicted in the long run.
About the Author:
Contact Voices Against Brain Cancer if you are searching for more information about glioblastoma research.
By Rob Sutter
When you're talking about the more prevalent type of tumor in the brain, glioblastoma research is definitely something worth talking about. The potential that this method can possess is one of the greatest that I have seen. There is a high level of work done on the matter, which is tough to argue against. With so many stories posted about the matter, I would like to think that I have placed all of my attention on those which are the most deserving, of which there are many.
For example, an article on Seeking Alpha talked about how the Northwest Biotherapeutics announced a 60-patient Phase I/II trial in order to work towards a related goal. The trial would be done at the MD Anderson Cancer Center and a type of immunotherapy would be put into effect as well. It has been given the name of DCVax-Direct and it will have a standard dose escalation phase, which will play into the Phase II portion. This would then determine a RECIST-measured tumor shrinkage endpoint, displaying a high level of intricacy.
One of the defining features of this experiment is that it makes use of a patient's own bodily cells. This doesn't seem to be much different from stem cell research, which is being conducted right now as well. There are many supporters of this, since they believe that something great will come of it in due time. It's difficult to argue such a thing and I believe that it's easy to make the comparison between one and the other, considering how certain cells are implemented.
Glioblastoma research is an important idea to consider, especially when you think about the common nature of these particular tumors. It seems like these are the ones most seen in an entire group; at least 120 types are known. I don't think that companies the likes of Voices against Brain Cancer will be able to deny this kind of idea, either. Hopefully there is more done in order to help those impacted and that these kinds of stories are reported on in the future.
It's clear that Northwest has done a great deal of good when it comes to this particular method. It seems like even more will be done in the future, as the article talked a phase III trial that would help the patients along. From what I've seen, solid results will come down the pipeline in 2014, which would be great for those working in this field of research. I believe that, with so many details in existence, it seems like even more of them will be able to help those afflicted in the long run.
For example, an article on Seeking Alpha talked about how the Northwest Biotherapeutics announced a 60-patient Phase I/II trial in order to work towards a related goal. The trial would be done at the MD Anderson Cancer Center and a type of immunotherapy would be put into effect as well. It has been given the name of DCVax-Direct and it will have a standard dose escalation phase, which will play into the Phase II portion. This would then determine a RECIST-measured tumor shrinkage endpoint, displaying a high level of intricacy.
One of the defining features of this experiment is that it makes use of a patient's own bodily cells. This doesn't seem to be much different from stem cell research, which is being conducted right now as well. There are many supporters of this, since they believe that something great will come of it in due time. It's difficult to argue such a thing and I believe that it's easy to make the comparison between one and the other, considering how certain cells are implemented.
Glioblastoma research is an important idea to consider, especially when you think about the common nature of these particular tumors. It seems like these are the ones most seen in an entire group; at least 120 types are known. I don't think that companies the likes of Voices against Brain Cancer will be able to deny this kind of idea, either. Hopefully there is more done in order to help those impacted and that these kinds of stories are reported on in the future.
It's clear that Northwest has done a great deal of good when it comes to this particular method. It seems like even more will be done in the future, as the article talked a phase III trial that would help the patients along. From what I've seen, solid results will come down the pipeline in 2014, which would be great for those working in this field of research. I believe that, with so many details in existence, it seems like even more of them will be able to help those afflicted in the long run.
About the Author:
Contact Voices Against Brain Cancer if you are searching for more information about glioblastoma research.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment